Ark Therapeutics names head of business development
13 June 2012 17:24 in Medical Company Restructures
Ark Therapeutics has named Kassim Kolia as its new head of business development.
Mr Kolia joins the company from Watson Pharmaceuticals subsidiary Eden Biodesign, where he has worked since 2006, taking responsibility for spearheading the firm's contract development and manufacturing services.
Prior to this, he served in the roles of key account manager at Bachem and cyclic guanosine monophosphate line manager at Lonza Biologics.
At Ark, he will leverage his experience in business development in the global biotech manufacturing services sector to promote corporate growth.
Dr David Venables, executive director of manufacturing services at Ark, said: "Kassim's extensive experience in winning manufacturing service contracts will enable us to accelerate the development of our world-leading contract viral product development and manufacturing services capability."
Last month, the firm was awarded an EU Framework Programme 7 Grant for its work on a new treatment for foetal growth restriction during pregnancy as part of a University College London-led consortium.
Other news stories from 13/06/2012
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency